-
1
-
-
23044436187
-
Malignant mesothelioma
-
DOI 10.1016/S0140-6736(05)67025-0, PII S0140673605670250
-
Robinson BWS, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366:397-408. (Pubitemid 41073959)
-
(2005)
Lancet
, vol.366
, Issue.9483
, pp. 397-408
-
-
Robinson, B.W.S.1
Musk, A.W.2
Lake, R.A.3
-
2
-
-
36448963507
-
Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register
-
DOI 10.1016/j.ejca.2007.09.018, PII S0959804907007484
-
Marinaccio A, Binazzi A, Cauzillo G, Cavone D, Zotti RD, Ferrante P, et al.; Italian Mesothelioma Register (ReNaM) Working Group. Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 2007; 43:2722-2728. (Pubitemid 350161848)
-
(2007)
European Journal of Cancer
, vol.43
, Issue.18
, pp. 2722-2728
-
-
Marinaccio, A.1
Binazzi, A.2
Cauzillo, G.3
Cavone, D.4
Zotti, R.D.5
Ferrante, P.6
Gennaro, V.7
Gorini, G.8
Menegozzo, M.9
Mensi, C.10
Merler, E.11
Mirabelli, D.12
Montanaro, F.13
Musti, M.14
Pannelli, F.15
Romanelli, A.16
Scarselli, A.17
Tumino, R.18
-
3
-
-
63949087814
-
Occupational, domestic and environmental mesothelioma risks in the British population: A case-control study
-
Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, Peto J. Occupational, domestic and environmental mesothelioma risks in the British population: A case-control study. Br J Cancer 2009; 100:1175-1183.
-
(2009)
Br J Cancer
, vol.100
, pp. 1175-1183
-
-
Rake, C.1
Gilham, C.2
Hatch, J.3
Darnton, A.4
Hodgson, J.5
Peto, J.6
-
4
-
-
67650002101
-
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma
-
Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27:3007-3013.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3007-3013
-
-
Krug, L.M.1
Pass, H.I.2
Rusch, V.W.3
Kindler, H.L.4
Sugarbaker, D.J.5
Rosenzweig, K.E.6
-
5
-
-
78149450949
-
Malignant pleural mesothelioma. A population-based study of survival
-
Milano MT, Zhang H. Malignant pleural mesothelioma. A population-based study of survival. J Thorac Oncol 2010; 5:1841-1848.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1841-1848
-
-
Milano, M.T.1
Zhang, H.2
-
6
-
-
0032895398
-
Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study
-
Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 1999; 17:25-30. (Pubitemid 29022374)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.1
, pp. 25-30
-
-
Byrne, M.J.1
Davidson, J.A.2
Musk, A.W.3
Dewar, J.4
Van Hazel, G.5
Buck, M.6
De Klerk, N.H.7
Robinson, B.W.S.8
-
7
-
-
0002117722
-
Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: A phase II study of the GSTPV
-
Aversa SM, Favaretto AG. Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: A phase II study of the GSTPV. Clin Lung Cancer 1999; 1:73-77.
-
(1999)
Clin Lung Cancer
, vol.1
, pp. 73-77
-
-
Aversa, S.M.1
Favaretto, A.G.2
-
8
-
-
18244404869
-
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
-
DOI 10.1038/sj.bjc.6600118
-
Van Haarst JMW, Baas P, Manegold C, Schouwink JH, Burgers JA, de Bruin HG, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002; 86:342-345. (Pubitemid 34187648)
-
(2002)
British Journal of Cancer
, vol.86
, Issue.3
, pp. 342-345
-
-
Van Haarst, J.M.W.1
Baas, P.2
Manegold, Ch.3
Schouwink, J.H.4
Burgers, J.A.5
De Bruin, H.G.6
Mooi, W.J.7
Van Klaveren, R.J.8
De Jonge, M.J.A.9
Van Meerbeeck, J.P.10
-
9
-
-
0037183683
-
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
-
Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87:491-496.
-
(2002)
Br J Cancer
, vol.87
, pp. 491-496
-
-
Nowak, A.K.1
Byrne, M.J.2
Williamson, R.3
Ryan, G.4
Segal, A.5
Fielding, D.6
-
10
-
-
0037844997
-
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: A multicentric phase II study
-
DOI 10.1002/cncr.11405
-
Favaretto AG, Aversa SM, Paccagnella A, Manzini Vde P, Palmisano V, Oniga F, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: A multicentric phase II study. Cancer 2003; 97:2791-2797. (Pubitemid 36605147)
-
(2003)
Cancer
, vol.97
, Issue.11
, pp. 2791-2797
-
-
Favaretto, A.G.1
Aversa, S.M.L.2
Paccagnella, A.3
Manzini, V.D.P.4
Palmisano, V.5
Oniga, F.6
Stefani, M.7
Rea, F.8
Bortolotti, L.9
Loreggian, L.10
Monfardini, S.11
-
11
-
-
20444374442
-
Cisplatin and gemcitabine in malignant pleural mesothelioma: A phase II study
-
DOI 10.1097/01.coc.0000144852.75613.56
-
Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: A phase II study. Am J Clin Oncol 2005; 28:223-226. (Pubitemid 40800471)
-
(2005)
American Journal of Clinical Oncology: Cancer Clinical Trials
, vol.28
, Issue.3
, pp. 223-226
-
-
Castagneto, B.1
Zai, S.2
Dongiovanni, D.3
Muzio, A.4
Bretti, S.5
Numico, G.6
Botta, M.7
-
12
-
-
42949152330
-
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810)
-
DOI 10.1016/j.lungcan.2007.09.018, PII S0169500207005636
-
Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008; 60:259-263. (Pubitemid 351609140)
-
(2008)
Lung Cancer
, vol.60
, Issue.2
, pp. 259-263
-
-
Kalmadi, S.R.1
Rankin, C.2
Kraut, M.J.3
Jacobs, A.D.4
Petrylak, D.P.5
Adelstein, D.J.6
Keohan, M.L.7
Taub, R.N.8
Borden, E.C.9
-
13
-
-
0031406423
-
A Phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors
-
DOI 10.1023/A:1005981317532
-
Brand R, Capadano M, Tempero M. A phase I trial of weekly gemcitabine administered as prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 1997; 15:331-341. (Pubitemid 28098500)
-
(1997)
Investigational New Drugs
, vol.15
, Issue.4
, pp. 331-341
-
-
Brand, R.1
Capadano, M.2
Tempero, M.3
-
14
-
-
0031025090
-
Maximum-tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naive patients with advanced non- small-cell lung cancer
-
Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, et al. Maximum-tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 1997; 15:310-316. (Pubitemid 27020589)
-
(1997)
Journal of Clinical Oncology
, vol.15
, Issue.1
, pp. 310-316
-
-
Fossella, F.V.1
Lippman, S.M.2
Shin, D.M.3
Tarassoff, P.4
Calayag-Jung, M.5
Perez-Soler, R.6
Lee, J.S.7
Murphy, W.K.8
Glisson, B.9
Rivera, E.10
Hong, W.K.11
-
15
-
-
0031734416
-
Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors
-
DOI 10.1023/A:1008487932384
-
Touroutoglou N, Gravel D, Raber MN, Plunkett W, Abbruzzese JL. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 1998; 9: 1003-1008. (Pubitemid 28496710)
-
(1998)
Annals of Oncology
, vol.9
, Issue.9
, pp. 1003-1008
-
-
Touroutoglou, N.1
Gravel, D.2
Raber, M.N.3
Plunkett, W.4
Abbruzzese, J.L.5
-
16
-
-
0030035730
-
A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer
-
Anderson H, Thatcher N, Walling J, Hansen H. A phase I study of a 24 h infusion of gemcitabine in previously untreated patients with inoperable nonsmall-cell lung cancer. Br J Cancer 1996; 74:460-462. (Pubitemid 26254579)
-
(1996)
British Journal of Cancer
, vol.74
, Issue.3
, pp. 460-462
-
-
Anderson, H.1
Thatcher, N.2
Walling, J.3
Hansen, H.4
-
17
-
-
0030949235
-
2) levels
-
DOI 10.1023/A:1005817024382
-
Pollera CF, Ceribelli A, Crecco M, Oliva C, Calabresi F. Prolonged infusion gemcitabine: A clinical phase I study at low-(300 mg/m2) and high-dose (875 mg/m2) levels. Invest New Drugs 1997; 15:115-121. (Pubitemid 27248251)
-
(1997)
Investigational New Drugs
, vol.15
, Issue.2
, pp. 115-121
-
-
Pollera, C.F.1
Ceribelli, A.2
Crecco, M.3
Oliva, C.4
Calabresi, F.5
-
18
-
-
0032848366
-
Prolonged infusion of gemcitabine in stage IV breast cancer: A phase I study
-
Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthaler HG, et al. Prolonged infusion of gemcitabine in stage IV breast cancer: A phase I study. Anticancer Drugs 1999; 10:525-531. (Pubitemid 29410798)
-
(1999)
Anti-Cancer Drugs
, vol.10
, Issue.6
, pp. 525-531
-
-
Akrivakis, K.1
Schmid, P.2
Flath, B.3
Schweigert, M.4
Sezer, O.5
Mergenthaler, H.-G.6
Possinger, K.7
-
19
-
-
0034777961
-
Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors
-
DOI 10.1097/00001813-200110000-00001
-
Maurel J, Zorrilla M, Puertolas T, Antón A, Herrero A, Artal A, et al. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs 2001; 12:713-717. (Pubitemid 33001183)
-
(2001)
Anti-Cancer Drugs
, vol.12
, Issue.9
, pp. 713-717
-
-
Maurel, J.1
Zorrilla, M.2
Puertolas, T.3
Anton, A.4
Herrero, A.5
Artal, A.6
Alonso, V.7
Martinez-Trufero, J.8
Del Mar Puertas, M.9
-
20
-
-
0026101039
-
Saturation of 20,20-difluorodeoxycytidine 50-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine
-
Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 20,20-difluorodeoxycytidine 50-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991; 27:258-262.
-
(1991)
Cancer Chemother Pharmacol
, vol.27
, pp. 258-262
-
-
Grunewald, R.1
Abbruzzese, J.L.2
Tarassoff, P.3
Plunkett, W.4
-
21
-
-
0025978216
-
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
-
Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9:491-499.
-
(1991)
J Clin Oncol
, vol.9
, pp. 491-499
-
-
Abbruzzese, J.L.1
Grunewald, R.2
Weeks, E.A.3
Gravel, D.4
Adams, T.5
Nowak, B.6
-
22
-
-
33745621338
-
Pharmacokinetic evaluation of gemcitabine and 2′,2′- difluorodeoxycytidine-5′-triphosphate after prolonged infusion in patients affected by different solid tumors
-
DOI 10.1093/annonc/mdj970
-
Cattel L, Airoldi M, Delprino L, Passera R, Milla P, Pedani F. Pharmacokinetic evaluation of gemcitabine and 20,20-difluorodeoxycytidine-50- triphosphate after prolonged infusion in patients affected by different solid tumors. Ann Oncol 2006; 17 (Suppl 5):v142-v147. (Pubitemid 43985224)
-
(2006)
Annals of Oncology
, vol.17
, Issue.SUPPL. 5
-
-
Cattel, L.1
Airoldi, M.2
Delprino, L.3
Passera, R.4
Milla, P.5
Pedani, F.6
-
23
-
-
42949093133
-
Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer
-
DOI 10.1016/j.lungcan.2007.10.004, PII S0169500207006083
-
Xiong JP, Feng M, Qiu F, Xu J, Tao QS, Zhang L, et al. Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Lung Cancer 2008; 60:208-214. (Pubitemid 351609148)
-
(2008)
Lung Cancer
, vol.60
, Issue.2
, pp. 208-214
-
-
Xiong, J.P.1
Feng, M.2
Qiu, F.3
Xu, J.4
Tao, Q.S.5
Zhang, L.6
Xiang, X.J.7
Zhong, L.X.8
Yu, F.9
Ma, X.T.10
Gong, W.Y.11
-
24
-
-
69549143754
-
Treatment of advanced NSCLC (Stage IIIB and IV) with low dose gemcitabine and carboplatin [Abstract]
-
Parikh PM, Narayanan P, Mistry RC, Agarwal JP, Pai VR, Nair R, et al. Treatment of advanced NSCLC (Stage IIIB and IV) with low dose gemcitabine and carboplatin [Abstract]. J Clin Oncol 2005; 23 (Suppl 1):196 S.
-
(2005)
J Clin Oncol
, vol.23
, Issue.SUPPL. 1
-
-
Parikh, P.M.1
Narayanan, P.2
Mistry, R.C.3
Agarwal, J.P.4
Pai, V.R.5
Nair, R.6
-
25
-
-
0033911963
-
Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas
-
DOI 10.1097/00001813-200006000-00002
-
Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 2000; 11:325-329. (Pubitemid 30459467)
-
(2000)
Anti-Cancer Drugs
, vol.11
, Issue.5
, pp. 325-329
-
-
Spath-Schwalbe, E.1
Genvresse, I.2
Koschuth, A.3
Dietzmann, A.4
Grunewald, R.5
Possinger, K.6
-
26
-
-
0035090424
-
Achievement of complete remission in refractory Hodgkin's disease with prolonged infussion of gemcitabine
-
DOI 10.1023/A:1006478702342
-
Sezer O, Eucker J, Jakob C, Kaufmann O, Schmid P, Possinger K. Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine. Invest New Drugs 2001; 19:101-104. (Pubitemid 32209792)
-
(2001)
Investigational New Drugs
, vol.19
, Issue.1
, pp. 101-104
-
-
Sezer, O.1
Eucker, J.2
Jakob, C.3
Kaufmann, O.4
Schmid, P.5
Possinger, K.6
-
27
-
-
27644473616
-
Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: A phase II study
-
DOI 10.1007/s00432-005-0675-y
-
Schmid P, Heilmann V, Schulz CO, Dieing A, Lehenbauer-Dehm S, Jehn C, et al. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: A phase II study. J Cancer Res Clin Oncol 2005; 131:568-574. (Pubitemid 41558548)
-
(2005)
Journal of Cancer Research and Clinical Oncology
, vol.131
, Issue.9
, pp. 568-574
-
-
Schmid, P.1
Heilmann, V.2
Schulz, C.-O.3
Dieing, A.4
Lehenbauer-Dehm, S.5
Jehn, C.6
Sezer, O.7
Possinger, K.8
Flath, B.9
-
28
-
-
0242665443
-
Phase II Trial of a 24-Hour Infusion of Gemcitabine in Previously Untreated Patients with Advanced Pancreatic Adenocarcinoma
-
DOI 10.1081/CNV-120023767
-
Eckel F, Schmelz R, Erdmann J, Mayr M, Lersch C. Phase II trial of a 24-h infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. Cancer Invest 2003; 21:690-694. (Pubitemid 37377323)
-
(2003)
Cancer Investigation
, vol.21
, Issue.5
, pp. 690-694
-
-
Eckel, F.1
Schmelz, R.2
Erdmann, J.3
Mayr, M.4
Lersch, C.5
-
29
-
-
39649109062
-
Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: A Phase II trial
-
DOI 10.1016/j.urolonc.2007.01.013, PII S1078143907000063
-
Khaled H, Emara ME, Gaafar RM, Mansour O, AbdelWarith A, Zaghloul MS, et al. Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: A Phase II trial. Urol Oncol 2008; 26:133-136. (Pubitemid 351288557)
-
(2008)
Urologic Oncology: Seminars and Original Investigations
, vol.26
, Issue.2
, pp. 133-136
-
-
Khaled, H.1
Emara, M.E.2
Gaafar, R.M.3
Mansour, O.4
Abdel Warith, A.5
Zaghloul, M.S.6
El Malt, O.7
-
30
-
-
27644595794
-
Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer
-
DOI 10.1097/00001813-200511000-00013
-
Zwitter M, Kovac V, Smrdel U, Kocijancic I, Segedin B, Vrankar M. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs 2005; 16: 1129-1134. (Pubitemid 41565779)
-
(2005)
Anti-Cancer Drugs
, vol.16
, Issue.10
, pp. 1129-1134
-
-
Zwitter, M.1
Kovac, V.2
Smrdel, U.3
Kocijancic, I.4
Segedin, B.5
Vrankar, M.6
-
31
-
-
69549116226
-
Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: A randomized phase II clinical trial
-
Zwitter M, Kovac V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: A randomized phase II clinical trial. J Thorac Oncol 2009; 4:1148-1155.
-
(2009)
J Thorac Oncol
, vol.4
, pp. 1148-1155
-
-
Zwitter, M.1
Kovac, V.2
Smrdel, U.3
Vrankar, M.4
Zadnik, V.5
-
32
-
-
77953539831
-
Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: A phase II randomized trial
-
Zwitter M, Kovac V, Rajer M, Vrankar M, Smrdel U. Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: A phase II randomized trial. Anticancer Drugs 2010; 21:662-668.
-
(2010)
Anticancer Drugs
, vol.21
, pp. 662-668
-
-
Zwitter, M.1
Kovac, V.2
Rajer, M.3
Vrankar, M.4
Smrdel, U.5
-
33
-
-
2442418050
-
Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy
-
Socinski MA. Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy. Clin Lung Cancer 2004; 5:274-289. (Pubitemid 38618238)
-
(2004)
Clinical Lung Cancer
, vol.5
, Issue.5
, pp. 274-289
-
-
Socinski, M.A.1
-
34
-
-
79952265014
-
Pleural mesothelioma
-
UICC International Union Against Cancer, editor. 7th ed Chichester: Wiley-Blackwell.
-
Sobin LH, Gospodarowicz MK, Wittekind Ch. Pleural mesothelioma. In: UICC International Union Against Cancer, editor. TNM classification of malignant tumours. 7th ed. Chichester: Wiley-Blackwell. 2009; pp. 147-150.
-
(2009)
TNM Classification of Malignant Tumours
, pp. 147-150
-
-
Sobin, L.H.1
Gospodarowicz, M.K.2
Wittekind, C.3
-
35
-
-
1342267614
-
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
-
DOI 10.1093/annonc/mdh059
-
Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15:257-260. (Pubitemid 38262625)
-
(2004)
Annals of Oncology
, vol.15
, Issue.2
, pp. 257-260
-
-
Byrne, M.J.1
Nowak, A.K.2
-
36
-
-
0024536437
-
Optimal two-stage designs for phase II clinical trials
-
DOI 10.1016/0197-2456(89)90015-9
-
Simon R. Optimal designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10. (Pubitemid 19099520)
-
(1989)
Controlled Clinical Trials
, vol.10
, Issue.1
, pp. 1-10
-
-
Simon, R.1
-
37
-
-
0036137925
-
Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma
-
DOI 10.1200/JCO.20.1.274
-
Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002; 20:274-281. (Pubitemid 34032621)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.1
, pp. 274-281
-
-
Mikulski, S.M.1
Costanzi, J.J.2
Vogelzang, N.J.3
McCachren, S.4
Taub, R.N.5
Chun, H.6
Mittelman, A.7
Panella, T.8
Puccio, C.9
Fine, R.10
Shogen, K.11
-
38
-
-
0041629528
-
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
-
DOI 10.1200/JCO.2003.11.136
-
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-2644. (Pubitemid 46606305)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.14
, pp. 2636-2644
-
-
Vogelzang, N.J.1
Rusthoven, J.J.2
Symanowski, J.3
Denham, C.4
Kaukel, E.5
Ruffie, P.6
Gatzemeier, U.7
Boyer, M.8
Emri, S.9
Manegold, C.10
Niyikiza, C.11
Paoletti, P.12
-
39
-
-
27244447448
-
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
-
Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23:6881-6889.
-
(2005)
J Clin Oncol
, vol.23
, pp. 6881-6889
-
-
Van Meerbeeck, J.P.1
Gaafar, R.2
Manegold, C.3
Van Klaveren, R.J.4
Van Marck, E.A.5
Vincent, M.6
-
40
-
-
43249105802
-
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma
-
Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008; 26:1698-1704.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1698-1704
-
-
Jassem, J.1
Ramlau, R.2
Santoro, A.3
Schuette, W.4
Chemaissani, A.5
Hong, S.6
-
41
-
-
43449092540
-
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): A multicentre randomised trial
-
DOI 10.1016/S0140-6736(08)60727-8, PII S0140673608607278
-
Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): A multicentre randomised trial. Lancet 2008; 371:1685-1694. (Pubitemid 351671885)
-
(2008)
The Lancet
, vol.371
, Issue.9625
, pp. 1685-1694
-
-
Muers, M.F.1
Stephens, R.J.2
Fisher, P.3
Darlison, L.4
Higgs, C.M.5
Lowry, E.6
Nicholson, A.G.7
O'Brien, M.8
Peake, M.9
Rudd, R.10
Snee, M.11
Steele, J.12
Girling, D.J.13
Nankivell, M.14
Pugh, C.15
Parmar, M.K.16
-
42
-
-
58949097246
-
Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: A phase II study
-
Hillerdal G, Sorensen JB, Sundström S, Riska H, Vikström A, Hjerpe A. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: A phase II study. J Thorac Oncol 2008; 3:1325-1331.
-
(2008)
J Thorac Oncol
, vol.3
, pp. 1325-1331
-
-
Hillerdal, G.1
Sorensen, J.B.2
Sundström, S.3
Riska, H.4
Vikström, A.5
Hjerpe, A.6
-
43
-
-
50349092664
-
Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: Results of the International Expanded Access Program
-
Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: Results of the International Expanded Access Program. J Thorac Oncol 2008; 3:756-763.
-
(2008)
J Thorac Oncol
, vol.3
, pp. 756-763
-
-
Santoro, A.1
O'Brien, M.E.2
Stahel, R.A.3
Nackaerts, K.4
Baas, P.5
Karthaus, M.6
-
44
-
-
70349687645
-
The mesothelioma and radical surgery randomized controlled trial: The Mars feasibility study
-
Treasure T, Waller D, Tan C, Entwisle J, O'Brien M, O'Byrne K, et al. The mesothelioma and radical surgery randomized controlled trial: The Mars feasibility study. J Thorac Oncol 2009; 4:1254-1258.
-
(2009)
J Thorac Oncol
, vol.4
, pp. 1254-1258
-
-
Treasure, T.1
Waller, D.2
Tan, C.3
Entwisle, J.4
O'Brien, M.5
O'Byrne, K.6
-
45
-
-
33645449947
-
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
-
DOI 10.1200/JCO.2005.04.3190
-
Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24:1443-1448. (Pubitemid 46622011)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.9
, pp. 1443-1448
-
-
Ceresoli, G.L.1
Zucali, P.A.2
Favaretto, A.G.3
Grossi, F.4
Bidoli, P.5
Del Conte, G.6
Ceribelli, A.7
Bearz, A.8
Morenghi, E.9
Cavina, R.10
Marangolo, M.11
Soto Parra, H.J.12
Santoro, A.13
-
46
-
-
84855208311
-
-
Cancer Registry of Republic of Slovenia. Ljubljana: Institute of Oncology Ljubljana
-
Cancer Registry of Republic of Slovenia. Cancer incidence in Slovenia 2002-2008. Ljubljana: Institute of Oncology Ljubljana; 2005-2011.
-
(2005)
Cancer incidence in Slovenia 2002-2008
-
-
-
47
-
-
79951772961
-
A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria
-
Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol 2011; 6:598-601.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 598-601
-
-
Tsao, A.S.1
Garland, L.2
Redman, M.3
Kernstine, K.4
Gandara, D.5
Marom, E.M.6
-
48
-
-
0031961891
-
Prognostic factors in patients with pleural mesothelioma: The European organization for research and treatment of cancer experience
-
Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16:145-152. (Pubitemid 28041592)
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.1
, pp. 145-152
-
-
Curran, D.1
Sahmoud, T.2
Therasse, P.3
Van Meerbeeck, J.4
Postmus, P.E.5
Giaccone, G.6
-
49
-
-
58149083475
-
Systemic treatments for mesothelioma: Standard and novel
-
Kindler HL. Systemic treatments for mesothelioma: Standard and novel. Curr Treat Options Oncol 2008; 9:171-179.
-
(2008)
Curr Treat Options Oncol
, vol.9
, pp. 171-179
-
-
Kindler, H.L.1
-
50
-
-
77249101787
-
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: A phase II study
-
Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: A phase II study. Clin Lung Cancer 2010; 11:30-35.
-
(2010)
Clin Lung Cancer
, vol.11
, pp. 30-35
-
-
Katirtzoglou, N.1
Gkiozos, I.2
Makrilia, N.3
Tsaroucha, E.4
Rapti, A.5
Stratakos, G.6
-
51
-
-
70349454095
-
Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma
-
Wilcox BE, Subramaniam RM, Peller PJ, Aughenbaugh GL, Nichols Iii FC, Aubry MC, et al. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer 2009; 10:244-248.
-
(2009)
Clin Lung Cancer
, vol.10
, pp. 244-248
-
-
Wilcox, B.E.1
Subramaniam, R.M.2
Peller, P.J.3
Aughenbaugh, G.L.4
Nichols Iii, F.C.5
Aubry, M.C.6
-
52
-
-
77951807217
-
Chemotherapy induced pathologic complete response in malignant pleural mesothelioma: A review and case report
-
Bech C, Sørensen JB. Chemotherapy induced pathologic complete response in malignant pleural mesothelioma: A review and case report. J Thorac Oncol 2010; 5:735-740.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 735-740
-
-
Bech, C.1
Sørensen, J.B.2
-
53
-
-
79952186170
-
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
-
Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011; 72:73-77.
-
(2011)
Lung Cancer
, vol.72
, pp. 73-77
-
-
Ceresoli, G.L.1
Zucali, P.A.2
De Vincenzo, F.3
Gianoncelli, L.4
Simonelli, M.5
Lorenzi, E.6
-
54
-
-
38849115655
-
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)
-
DOI 10.1093/annonc/mdm501
-
Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19:370-373. (Pubitemid 351201722)
-
(2008)
Annals of Oncology
, vol.19
, Issue.2
, pp. 370-373
-
-
Castagneto, B.1
Botta, M.2
Aitini, E.3
Spigno, F.4
Degiovanni, D.5
Alabiso, O.6
Serra, M.7
Muzio, A.8
Carbone, R.9
Buosi, R.10
Galbusera, V.11
Piccolini, E.12
Giaretto, L.13
Rebella, L.14
Mencoboni, M.15
-
56
-
-
68549106008
-
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: A single institution phase II study
-
Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, et al. Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: A single institution phase II study. Anticancer Res 2009; 29:3441-3444.
-
(2009)
Anticancer Res
, vol.29
, pp. 3441-3444
-
-
Ralli, M.1
Tourkantonis, I.2
Makrilia, N.3
Gkini, E.4
Kotteas, E.5
Gkiozos, I.6
-
57
-
-
46349111832
-
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
-
DOI 10.1038/sj.bjc.6604421, PII 6604421
-
Sørensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008; 99:44-50. (Pubitemid 351920221)
-
(2008)
British Journal of Cancer
, vol.99
, Issue.1
, pp. 44-50
-
-
Sorensen, J.B.1
Frank, H.2
Palshof, T.3
-
58
-
-
67349198885
-
Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia
-
Lee CW, Murray N, Anderson H, Rao SC, Bishop W. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia. Lung Cancer 2009; 64:308-313.
-
(2009)
Lung Cancer
, vol.64
, pp. 308-313
-
-
Lee, C.W.1
Murray, N.2
Anderson, H.3
Rao, S.C.4
Bishop, W.5
|